New cream may ease skin complications after stem cell transplant

This study tests a cream containing ruxolitinib, a drug that targets inflammation, for treating a chronic skin condition called graft-versus-host disease (GVHD) that can occur after a stem cell transplant. About 24 participants will apply the cream to one side of their body and a standard moisturizer to the other, without knowing which is which. The goal is to see if the ruxolitinib cream safely reduces the affected skin area better than moisturizers alone.